Multi-centre, Randomised, Double-blind, Parallel-group Study to Compare Efficacy and Safety Between Anastrozole (ZD1033) and Tamoxifen in Pre- and Post-operative Administration Under Goserelin Acetate Treatment for Premenopausal Breast Cancer Patients.

Trial Profile

Multi-centre, Randomised, Double-blind, Parallel-group Study to Compare Efficacy and Safety Between Anastrozole (ZD1033) and Tamoxifen in Pre- and Post-operative Administration Under Goserelin Acetate Treatment for Premenopausal Breast Cancer Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Dec 2016

At a glance

  • Drugs Anastrozole (Primary) ; Goserelin; Tamoxifen
  • Indications Early breast cancer
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms STAGE
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Sep 2012 Results of an exploratory analysis of Ki-67 expression published in Cancer.
    • 19 Jan 2012 Results published in Lancet Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top